ASTRAZENECA PLC-SPONS ADR (AZN) Fundamental Analysis & Valuation
NYSE:AZN • US0463531089
Current stock price
204.8 USD
+4.33 (+2.16%)
At close:
204.8 USD
0 (0%)
After Hours:
This AZN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. AZN Profitability Analysis
1.1 Basic Checks
- AZN had positive earnings in the past year.
- AZN had a positive operating cash flow in the past year.
- Each year in the past 5 years AZN has been profitable.
- Each year in the past 5 years AZN had a positive operating cash flow.
1.2 Ratios
- AZN has a Return On Assets of 8.96%. This is amongst the best in the industry. AZN outperforms 90.05% of its industry peers.
- AZN has a Return On Equity of 21.01%. This is amongst the best in the industry. AZN outperforms 91.62% of its industry peers.
- AZN has a Return On Invested Capital of 13.63%. This is amongst the best in the industry. AZN outperforms 92.67% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for AZN is in line with the industry average of 13.11%.
- The last Return On Invested Capital (13.63%) for AZN is above the 3 year average (12.48%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.96% | ||
| ROE | 21.01% | ||
| ROIC | 13.63% |
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
1.3 Margins
- The Profit Margin of AZN (17.41%) is better than 90.05% of its industry peers.
- AZN's Profit Margin has improved in the last couple of years.
- AZN's Operating Margin of 23.86% is amongst the best of the industry. AZN outperforms 91.10% of its industry peers.
- In the last couple of years the Operating Margin of AZN has grown nicely.
- AZN has a better Gross Margin (81.31%) than 86.39% of its industry peers.
- AZN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.86% | ||
| PM (TTM) | 17.41% | ||
| GM | 81.31% |
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
2. AZN Health Analysis
2.1 Basic Checks
- AZN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- AZN has about the same amout of shares outstanding than it did 1 year ago.
- AZN has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for AZN has been reduced compared to a year ago.
2.2 Solvency
- An Altman-Z score of 3.91 indicates that AZN is not in any danger for bankruptcy at the moment.
- AZN has a Altman-Z score of 3.91. This is in the better half of the industry: AZN outperforms 68.59% of its industry peers.
- AZN has a debt to FCF ratio of 3.42. This is a good value and a sign of high solvency as AZN would need 3.42 years to pay back of all of its debts.
- AZN has a Debt to FCF ratio of 3.42. This is amongst the best in the industry. AZN outperforms 89.53% of its industry peers.
- A Debt/Equity ratio of 0.55 indicates that AZN is somewhat dependend on debt financing.
- AZN has a worse Debt to Equity ratio (0.55) than 67.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.42 | ||
| Altman-Z | 3.91 |
ROIC/WACC1.54
WACC8.87%
2.3 Liquidity
- AZN has a Current Ratio of 0.94. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
- AZN has a worse Current ratio (0.94) than 88.48% of its industry peers.
- AZN has a Quick Ratio of 0.94. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 0.72, AZN is doing worse than 86.91% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.72 |
3. AZN Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an nice 11.57% over the past year.
- The Earnings Per Share has been growing by 17.91% on average over the past years. This is quite good.
- Looking at the last year, AZN shows a quite strong growth in Revenue. The Revenue has grown by 8.63% in the last year.
- Measured over the past years, AZN shows a quite strong growth in Revenue. The Revenue has been growing by 17.15% on average per year.
EPS 1Y (TTM)11.57%
EPS 3Y11.21%
EPS 5Y17.91%
EPS Q2Q%1.44%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%
3.2 Future
- Based on estimates for the next years, AZN will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.35% on average per year.
- The Revenue is expected to grow by 6.31% on average over the next years.
EPS Next Y14.55%
EPS Next 2Y13.63%
EPS Next 3Y12.24%
EPS Next 5Y11.35%
Revenue Next Year7.34%
Revenue Next 2Y6.89%
Revenue Next 3Y6.56%
Revenue Next 5Y6.31%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. AZN Valuation Analysis
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 22.19, AZN is valued on the expensive side.
- 82.20% of the companies in the same industry are more expensive than AZN, based on the Price/Earnings ratio.
- The average S&P500 Price/Earnings ratio is at 27.87. AZN is valued slightly cheaper when compared to this.
- A Price/Forward Earnings ratio of 19.37 indicates a rather expensive valuation of AZN.
- 79.58% of the companies in the same industry are more expensive than AZN, based on the Price/Forward Earnings ratio.
- Compared to an average S&P500 Price/Forward Earnings ratio of 38.51, AZN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.19 | ||
| Fwd PE | 19.37 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AZN indicates a rather cheap valuation: AZN is cheaper than 80.63% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, AZN is valued cheaper than 80.10% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.63 | ||
| EV/EBITDA | 16.92 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- The excellent profitability rating of AZN may justify a higher PE ratio.
- A more expensive valuation may be justified as AZN's earnings are expected to grow with 12.24% in the coming years.
PEG (NY)1.53
PEG (5Y)1.24
EPS Next 2Y13.63%
EPS Next 3Y12.24%
5. AZN Dividend Analysis
5.1 Amount
- AZN has a Yearly Dividend Yield of 1.55%.
- Compared to an average industry Dividend Yield of 0.42, AZN pays a better dividend. On top of this AZN pays more dividend than 91.62% of the companies listed in the same industry.
- Compared to an average S&P500 Dividend Yield of 1.82, AZN has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.55% |
5.2 History
- The dividend of AZN has a limited annual growth rate of 3.33%.
- AZN has been paying a dividend for at least 10 years, so it has a reliable track record.
- AZN has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)3.33%
Div Incr Years2
Div Non Decr Years12
5.3 Sustainability
- AZN pays out 48.62% of its income as dividend. This is a bit on the high side, but may be sustainable.
- AZN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP48.62%
EPS Next 2Y13.63%
EPS Next 3Y12.24%
AZN Fundamentals: All Metrics, Ratios and Statistics
204.8
+4.33 (+2.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-10 2026-02-10/bmo
Earnings (Next)04-29 2026-04-29
Inst Owners52.17%
Inst Owner Change-99.72%
Ins Owners0.04%
Ins Owner Change0%
Market Cap317.61B
Revenue(TTM)58.74B
Net Income(TTM)10.22B
Analysts81.67
Price Target220.72 (7.77%)
Short Float %0.11%
Short Ratio0.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.55% |
Yearly Dividend3.21
Dividend Growth(5Y)3.33%
DP48.62%
Div Incr Years2
Div Non Decr Years12
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.02%
Min EPS beat(2)-1.5%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)0.45%
Min EPS beat(4)-7.49%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.6%
EPS beat(12)7
Avg EPS beat(12)1.6%
EPS beat(16)11
Avg EPS beat(16)2.81%
Revenue beat(2)0
Avg Revenue beat(2)-1.57%
Min Revenue beat(2)-2.88%
Max Revenue beat(2)-0.26%
Revenue beat(4)0
Avg Revenue beat(4)-3.05%
Min Revenue beat(4)-5.08%
Max Revenue beat(4)-0.26%
Revenue beat(8)3
Avg Revenue beat(8)-0.6%
Revenue beat(12)4
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-0.82%
PT rev (1m)6.1%
PT rev (3m)126.73%
EPS NQ rev (1m)-0.96%
EPS NQ rev (3m)93.55%
EPS NY rev (1m)-0.86%
EPS NY rev (3m)101.98%
Revenue NQ rev (1m)0.39%
Revenue NQ rev (3m)0.63%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)1.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.19 | ||
| Fwd PE | 19.37 | ||
| P/S | 5.41 | ||
| P/FCF | 36.63 | ||
| P/OCF | 21.79 | ||
| P/B | 6.53 | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.92 |
EPS(TTM)9.23
EY4.51%
EPS(NY)10.57
Fwd EY5.16%
FCF(TTM)5.59
FCFY2.73%
OCF(TTM)9.4
OCFY4.59%
SpS37.88
BVpS31.38
TBVpS-6.72
PEG (NY)1.53
PEG (5Y)1.24
Graham Number80.7285 (-60.58%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.96% | ||
| ROE | 21.01% | ||
| ROCE | 16.8% | ||
| ROIC | 13.63% | ||
| ROICexc | 14.63% | ||
| ROICexgc | 59.47% | ||
| OM | 23.86% | ||
| PM (TTM) | 17.41% | ||
| GM | 81.31% | ||
| FCFM | 14.76% |
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
ROICexc(3y)13.49%
ROICexc(5y)11.39%
ROICexgc(3y)81.92%
ROICexgc(5y)83.55%
ROCE(3y)15.36%
ROCE(5y)12.92%
ROICexgc growth 3Y-25.55%
ROICexgc growth 5Y0.81%
ROICexc growth 3Y9.13%
ROICexc growth 5Y9.72%
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.42 | ||
| Debt/EBITDA | 1.36 | ||
| Cap/Depr | 103% | ||
| Cap/Sales | 10.05% | ||
| Interest Coverage | 10.65 | ||
| Cash Conversion | 73.79% | ||
| Profit Quality | 84.79% | ||
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 3.91 |
F-Score7
WACC8.87%
ROIC/WACC1.54
Cap/Depr(3y)80.57%
Cap/Depr(5y)64.46%
Cap/Sales(3y)8.93%
Cap/Sales(5y)7.69%
Profit Quality(3y)99.49%
Profit Quality(5y)775.68%
High Growth Momentum
Growth
EPS 1Y (TTM)11.57%
EPS 3Y11.21%
EPS 5Y17.91%
EPS Q2Q%1.44%
EPS Next Y14.55%
EPS Next 2Y13.63%
EPS Next 3Y12.24%
EPS Next 5Y11.35%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%
Revenue Next Year7.34%
Revenue Next 2Y6.89%
Revenue Next 3Y6.56%
Revenue Next 5Y6.31%
EBIT growth 1Y10.05%
EBIT growth 3Y16.67%
EBIT growth 5Y26.09%
EBIT Next Year25.58%
EBIT Next 3Y14.44%
EBIT Next 5Y10.4%
FCF growth 1Y19.18%
FCF growth 3Y6.21%
FCF growth 5Y31.64%
OCF growth 1Y22.88%
OCF growth 3Y14.12%
OCF growth 5Y24.88%
ASTRAZENECA PLC-SPONS ADR / AZN Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for ASTRAZENECA PLC-SPONS ADR?
ChartMill assigns a fundamental rating of 6 / 10 to AZN.
What is the valuation status for AZN stock?
ChartMill assigns a valuation rating of 6 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.
What is the profitability of AZN stock?
ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.
What is the valuation of ASTRAZENECA PLC-SPONS ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 22.19 and the Price/Book (PB) ratio is 6.53.
Is the dividend of ASTRAZENECA PLC-SPONS ADR sustainable?
The dividend rating of ASTRAZENECA PLC-SPONS ADR (AZN) is 7 / 10 and the dividend payout ratio is 48.62%.